GlassScriptPhysician profile
Danielle Ello Cruto
NPI 1497246961
$3,153.43
in general payments reported to CMS, 2019-2025
19 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.01 · 2021: $41.12 · 2024: $1,129 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.86 |
| Education | $176.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,343.52 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $421.29 | 2024-2025 | |
| Ucb, INC. | $262.78 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $223.46 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $128.33 | 2024-2025 | Hadlima, Vtama |
| Novartis Pharmaceuticals Corporation | $111.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $93.34 | 2024-2025 | Sotyktu |
| Biowound Solutions, INC. | $81.22 | 2025 | Bio-Connekt |
| Regeneron Healthcare Solutions, INC. | $73.06 | 2024-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.09 | 2025 | Spevigo |
| Galderma Laboratories, L.P. | $65.16 | 2025 | Nemluvio |
| Incyte Corporation | $64.39 | 2024-2025 | Opzelura |
| Genzyme Corporation | $59.96 | 2025 | |
| Leo Pharma INC. | $40.22 | 2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $29.06 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.64 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $23.48 | 2021 | |
| Amgen INC. | $22.86 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ello Cruto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.